

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

KING DRUG COMPANY OF FLORENCE, INC., <u>et al.</u> , Plaintiffs, v. CEPHALON, INC., <u>et al.</u> , Defendants.	:	CIVIL ACTION No. 2:06-cv-1797
VISTA HEALTHPLAN, INC., <u>et al.</u> , Plaintiffs, v. CEPHALON, INC., <u>et al.</u> , Defendants.	:	CIVIL ACTION No. 2:06-cv-1833
APOTEX, INC., Plaintiff, v. CEPHALON, INC., <u>et al.</u> , Defendants.	:	CIVIL ACTION No. 2:06-cv-2768
FEDERAL TRADE COMMISSION, Plaintiff, v. CEPHALON, INC., Defendant.	:	CIVIL ACTION No. 2:08-cv-2141

ORDER

AND NOW, this 9th day of January, 2014, upon consideration of the submissions of the parties,¹ and in particular the issues addressed in Cephalon's "Consolidated Opposition to Plaintiffs' Motions Seeking Summary Judgment or Preclusion on Walker Process Fraud and Other Antitrust Issues From the Bifurcated Patent Litigation," it is **ORDERED** that oral argument will take place on **Wednesday, January 22, at 10:00 a.m.**, in Courtroom 4B. Counsel shall be prepared to address the effect, if any, that the invalidity rulings set forth in Apotex, Inc. v. Cephalon, Inc., No. 06-2768, will have on the upcoming antitrust trial.

BY THE COURT:

/s/ Mitchell S. Goldberg

Mitchell S. Goldberg, J.

1

- Direct Purchaser Plaintiffs' Motion for Partial Summary Judgment on the Patent Issues (No. 06-1797, Doc. No. 518).
- End-Payor Plaintiffs' Motion for Partial Summary Judgment, limited to the issue of the collateral estoppel effect of the conclusions in Apotex v. Cephalon (No. 06-1833, Doc. No. 233).
- Apotex's Motion for Partial Summary Judgment, limited to the issue of antitrust liability (No. 06-2768, Doc. No. 601).
- FTC's Motion for Preclusion of the Patent Issues or Partial Summary Judgment (No. 08-2141, Doc. No. 218).